Evidence map›Paper›PMID 27151581›Full record

ArticleIntegrative cancer therapies2017

Probiotic Survey in Cancer Patients Treated in the Outpatient Department in a Comprehensive Cancer Center.

Sona Ciernikova, Michal Mego, Maria Semanova, Lenka Wachsmannova, Zuzana Adamcikova, Viola Stevurkova, Lubos Drgona, Vladimir Zajac

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Integrative cancer therapies, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03742596 (Effect of Probiotics Supplementation on the Side Effects of Radiation Therapy on the Immune System Among Colorectal Cancer Patients), which is not on this map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
3.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03742596 phase2 / phase3withdrawnnot on this mapstarted 2018, after this paper: background citation

Effect of Probiotics Supplementation on the Side Effects of Radiation Therapy on the Immune System Among Colorectal Cancer Patients

TypeinterventionalSponsorKing Hussein Cancer CenterRan2018 to 2022Enrolled0ConditionsColorectal CancerArmsProbiotic Formula Capsule, Control
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Sona Ciernikova1 Cancer Research Institute BMC, Slovak Academy of Sciences, Bratislava, Slovakia.
Michal Mego2 Comenius University, Bratislava, Slovakia.
Maria Semanova2 Comenius University, Bratislava, Slovakia.
Lenka Wachsmannova1 Cancer Research Institute BMC, Slovak Academy of Sciences, Bratislava, Slovakia.
Zuzana Adamcikova1 Cancer Research Institute BMC, Slovak Academy of Sciences, Bratislava, Slovakia.
Viola Stevurkova1 Cancer Research Institute BMC, Slovak Academy of Sciences, Bratislava, Slovakia.
Lubos Drgona2 Comenius University, Bratislava, Slovakia.
Vladimir Zajac1 Cancer Research Institute BMC, Slovak Academy of Sciences, Bratislava, Slovakia.
Comenius University Bratislava · SKSlovak Academy of Sciences · SKCancer Research Institute of the Slovak Academy of Sciences · SK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAvailability without prescription restriction, low cost, and simple oral administration allow cancer patients to use probiotics without knowledge of potential risks. We present a survey of probiotic use and the association with patient tumor characteristics in cancer patients treated at the outpatient department of the National Cancer Institute in Slovakia. PATIENTS AND

methodsBetween March and December 2014, 499 patients were asked to evaluate their overall experience with probiotics by questionnaire form, including the length and method of use relative to anticancer therapy, expectations, side-effect experiences, understanding of the possible risks, dietary supplement use, and others. The relevant data were statistically evaluated.

resultsThe cohort consisted of 323 women (64.7%) and 176 men (35.3%); 91.6% were undergoing chemotherapy (2.6% together with radiotherapy) and 8.4% had no anticancer therapy. The prevalence of probiotic use was 28.5% and only 12 patients using probiotics (8.5%) described negative side effects. Most patients declared consideration of probiotic use based on recommendation from a physician (37.3%) or a pharmacist (14.8%). Nevertheless, up to 86.6% of patients declared no knowledge of possible risks. Statistically significant correlation was found between probiotic use and age of patients (P < .008), gender (P < .023), and taking other dietary supplements (P < .000002).

conclusionsIn this prospective study, we present for the first time the prevalence, side-effect experience, and aspects that most likely influence probiotic use in cancer patients. Minimal knowledge of risks underlines the importance of an active approach by oncologists to inform patients about probiotic safety.

Indexed as

Antineoplastic AgentsDietary SupplementsFemaleHumansMaleMiddle AgedNeoplasmsOutpatientsPrevalenceProbioticsProspective StudiesSlovakiaSurveys and QuestionnairesAntineoplastic Agentscancerchemotherapydietary supplementsimmunocompromised cancer patientsoncologist to patient communicationprobioticssafety

Identifiers

PMID27151581
PMCPMC5739119
OpenAlexW2346826610

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.